ストックスクリーナーアプリを入手
4.43
7.90%
-0.38
アフターアワーズ：
4.43
Y Mabs Therapeutics Inc (YMAB) 最新ニュース
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stake Boosted by Charles Schwab Investment Management Inc. - Defense World
Top Premarket Decliners - MarketScreener
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
HC Wainwright Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World
Breaking Down Y-mAbs Therapeutics: 5 Analysts Share Their Views - Benzinga
Learn to Evaluate (YMAB) using the Charts - news.stocktradersdaily.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Y-mabs therapeutics CBO Gad Thomas sells $56,536 in stock - Investing.com India
Y-mabs therapeutics CEO Michael Rossi sells $20,368 in stock By Investing.com - Investing.com South Africa
Y-mabs therapeutics CBO Gad Thomas sells $56,536 in stock By Investing.com - Investing.com Australia
Y-mabs therapeutics CEO Michael Rossi sells $20,368 in stock - Investing.com
Y-mAbs Therapeutics Executives Sell Shares - TradingView
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates - MSN
YMAB Q1 EPS Estimate Boosted by Brookline Capital Management - MarketBeat
Bearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimates - Yahoo Finance UK
FY2025 EPS Estimates for YMAB Reduced by Cantor Fitzgerald - Defense World
Wedbush Reduces Earnings Estimates for Y-mAbs Therapeutics - Defense World
Brookline Capital Management Predicts YMAB Q1 Earnings - Defense World
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025 - Baystreet.ca
Y-mAbs Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St
Truist Financial Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World
Bank of America Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00 - Defense World
Morgan Stanley Issues Pessimistic Forecast for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World
Forecasting The Future: 4 Analyst Projections For Y-mAbs Therapeutics - Benzinga
Y-mAbs Therapeutics price target lowered to $12 from $14 at BofA - TipRanks
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2024 Earnings Call Transcript - Insider Monkey
Oppenheimer Adjusts Y-mAbs Therapeutics Price Target to $21 From $23, Maintains Outperform Rating - Marketscreener.com
Truist Cuts Price Target on Y-mAbs Therapeutics to $18 From $21, Keeps Buy Rating -March 05, 2025 at 06:27 am EST - Marketscreener.com
Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Call Highlights: Strategic Realignment and ... By GuruFocus - Investing.com Canada
Y-mAbs Therapeutics Reports 2024 Financial Results - TipRanks
Y-mAbs Therapeutics’ Earnings Call Highlights Mixed Results - TipRanks
Y-mAbs Therapeutics inks equity deal up to $35M - Investing.com India
Y-mAbs Therapeutics Inc Enters Equity Distribution Agreement With Oppenheimer -March 04, 2025 at 04:32 pm EST - Marketscreener.com
Y-mAbs Therapeutics inks equity deal up to $35M By Investing.com - Investing.com UK
SEC Form 424B5 filed by Y-mAbs Therapeutics Inc. - Quantisnow
Y-mAbs stock price target cut to $19 at Cantor Fitzgerald - Investing.com UK
Wedbush Cuts Price Target on Y-mAbs Therapeutics to $21 From $23, Keeps Outperform Rating - Marketscreener.com
Y-mAbs Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years ago - Yahoo Finance
Y-mAbs announces publication of Phase 2 interim results on naxitamab - Yahoo Finance
Y-mAbs Therapeutics Reports Fourth Quarter 2024 Financial Results - TradingView
Y-mAbs Reports Fourth Quarter 2024 Financial Results -March 04, 2025 at 07:06 am EST - Marketscreener.com
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments - The Manila Times
Y-mAbs Therapeutics reports Q4 EPS (15c), consensus (13c) - TipRanks
Y-mAbs Therapeutics (NASDAQ:YMAB) Given “Outperform” Rating at Wedbush - Defense World
Leptomeningeal Metastases Market Anticipated to Expand - openPR
Naxitamab shows promise in neuroblastoma phase 2 trial - Investing.com
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications - The Manila Times
Y-mAbs Therapeutics Publishes Positive Interim Data on Naxitamab for High-Risk Neuroblastoma in Nature Communications - Nasdaq
Can Y-mAbs' Neuroblastoma Therapy Turn 93% Survival Rate Into FDA Approval? - StockTitan
How the (YMAB) price action is used to our Advantage - Stock Traders Daily
YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Filed - ACCESS Newswire
Y MABS THERAPEUTICS Earnings Preview: Recent $YMAB Insider Trading, Hedge Fund Activity, and More - Nasdaq
Y-mAbs Therapeutics (YMAB) Expected to Announce Earnings on Tuesday - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Y-mAbs Therapeutics (YMAB) to Release Earnings on Tuesday - MarketBeat
Shareholders in Y-mAbs Therapeutics (NASDAQ:YMAB) are in the red if they invested five years ago - Simply Wall St
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):